Intra-Cellular Therapies Inc. (ITCI)
| Market Cap | 2.81B |
| Revenue (ttm) | 22.81M |
| Net Income (ttm) | -227.01M |
| Shares Out | 70.36M |
| EPS (ttm) | -3.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $34.67 |
| Previous Close | $33.27 |
| Change ($) | 1.40 |
| Change (%) | 4.21% |
| Day's Open | 33.60 |
| Day's Range | 32.24 - 34.81 |
| Day's Volume | 778,247 |
| 52-Week Range | 10.93 - 40.01 |
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 10.59% and 0.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in...
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients,...
Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder i...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent...
Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for centr...
The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.
After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes....
These two biotech companies are safe bargains in today's volatile market.
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for centr...
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 17.71% and 12.97%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) remained unaffected after the company reported Q3 results.
P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for ce...
These companies show that specialization can be an excellent competitive strategy.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for centr...
The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ce...
Shares of a New York City biotechnology company shot up nearly 73% Wednesday, sparked by news that a drug it's testing could hit sales of more than $1 billion, earning it blockbuster status.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten ...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering ...
Intra-Cellular Therapies (ITCI) is in the news Wednesday after announcing positive results from a recent study that sent ITCU stock soaring. The post Intra-Cellular Therapies News: Why ITCI St...
Intra-Cellular Therapies on Wednesday revealed positive final-phase test results for a treatment for certain Bipolar I and Bipolar II disorders, sending ITCI stock soaring more than 70%. The p...
Investors are reacting enthusiastically to the company's latest clinical results.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipola...
Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ce...
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for ...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries withou...
Intra-Cellular (ITCI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The 2020 year is practically halfway done, and this has really been the year of the biotech.
Intra-Cellular Therapies (ITCI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor in Intra-Cellular Therapies
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cen...
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ce...
The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of th...
Intra-Cellular Therapies sees its Relative Strength Rating move into the elite 90-plus level. The post Stocks To Watch: Intra-Cellular Therapies Sees Relative Strength Rating Rise To 93 appear...
About ITCI
Intra-Cellular Therapies, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substan... [Read more...]
| Industry Biotechnology | |
| CEO Sharon Mates | Employees 383 |
| Stock Exchange NASDAQ | Ticker Symbol ITCI |
Financial Performance
In 2020, ITCI's revenue was $22.81 million, an increase of 37,537.11% compared to the previous year's $60,613. Losses were -$227.01 million, 53.7% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is 51.38, which is an increase of 48.20% from the latest price.